Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01247194 · ClinicalTrials.gov registry record · Phase 1

A Phase 1b Study of PPI-461 in Patients With HCV Genotype 1

A Phase 1 study, sponsored by Presidio Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase
24
Enrollment target

NCT01247194: Completed Phase 1 study, sponsored by Presidio Pharmaceuticals.

NCT01247194 is a Phase 1 study that has completed, run by Presidio Pharmaceuticals. The registered enrollment target is 24 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01247194, a Phase 1 study, has completed, sponsored by Presidio Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase
24 participants
Enrollment target

Study Summary

The purpose of the study is to assess the safety, tolerability, antiviral effects, and pharmacokinetics of PPI-461 in patients with chronic hepatitis C virus genotype 1 infection.

Interventions

  • DRUG Placebo
  • DRUG PPI-461

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2010-10
Est. Completion 2011-06
Phase Phase 1
Presidio Pharmaceuticals

6 total trials

What the finished NCT01247194 record still lists

NCT01247194 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% lower).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT01247194 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01247194 about?

NCT01247194 is a clinical study titled "A Phase 1b Study of PPI-461 in Patients With HCV Genotype 1". The purpose of the study is to assess the safety, tolerability, antiviral effects, and pharmacokinetics of PPI-461 in patients with chronic hepatitis C virus genotype 1 infection.

What is the current status of trial NCT01247194?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2010-10. Estimated completion is 2011-06.

What interventions are being tested in trial NCT01247194?

The interventions under investigation include: Placebo (DRUG), PPI-461 (DRUG).

Who is sponsoring clinical trial NCT01247194?

This trial is sponsored by Presidio Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01247194's enrollment target sits among peer trials

24 1520th of 2000 higher than 405 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02331979 · 24 participants · NA

    Improving Bladder Function in SCI by Neuromodulation

  • NCT03096197 · 24 participants · NA

    Exoskeleton and Spinal Cord Stimulation for SCI

  • NCT03223922 · 24 participants · NA

    Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases

  • NCT03326921 · 24 participants · Phase 1

    HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01247194, the US trial registry maintained by the National Library of Medicine. NCT01247194 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.